Nivolumab Combined With BMS-986253 in HCC Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
A phase II clinical trial is utilized to examine whether BMS‐986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
Epistemonikos ID: 039a967ed6cc6b8108504f185ef1050c3c664db8
First added on: May 22, 2024